Symphogen has established itself as the leader in the development of antibody mixtures, and is pioneering a new approach to develop products targeting multiple oncology targets in a single drug product, more efficacious antibody therapeutics to treat serious human diseases. Symphogen captures the diversity and specificity of the natural immune response in rationally designed recombinant antibody mixtures.
The Symphogen pipeline is based upon a combination of proprietary platforms: a unique antibody discovery platform call Symplex TM, a functional lead selection platform called SymSelect TM, a manufacturing platform called Sympress TM and a number of antibody characterization technologies. The Company has established drug discovery, pre-clinical and early clinical drug development capabilities and infrastructure, and is now expanding its capabilities in the cancer biology arena to support creation of a pipeline of new cancer therapeutics that provide a significant benefit to patients.
Symphogen is based in Copenhagen, Denmark and employs a total of 90 people.